Stay updated on ROSCO-CF Safety in F508del-CFTR Homozygous Clinical Trial
Sign up to get notified when there's something new on the ROSCO-CF Safety in F508del-CFTR Homozygous Clinical Trial page.

Latest updates to the ROSCO-CF Safety in F508del-CFTR Homozygous Clinical Trial page
- Check2 days agoChange DetectedAdded a Locations section with France as a study site and updated the page revision to v3.3.3; the old France Locations entry was removed.SummaryDifference0.2%

- Check9 days agoChange DetectedAdded a Publications entry with a 2022 safety and pharmacokinetics citation and a Study Results section. Updated the France Locations to reflect current sites and removed some earlier listings, with the last update dated 2025-12-05.SummaryDifference1%

- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedThe page revision notice was updated from Revision: v3.2.0 to Revision: v3.3.2 in the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check38 days agoChange DetectedDeleted the notice about a lapse in government funding that warned information may not be up to date and directed users to opm.gov for status updates. The page no longer includes the operating status disclaimer or related guidance.SummaryDifference0.4%

- Check52 days agoChange DetectedThere are no significant changes between the old and new screenshots; the Study Details page content and structure appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check81 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference3%

Stay in the know with updates to ROSCO-CF Safety in F508del-CFTR Homozygous Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ROSCO-CF Safety in F508del-CFTR Homozygous Clinical Trial page.